Rare diseases in Europe: From a wide to a local perspective

Israel Medical Association Journal

Volumn 18, Issue 6, 2016, Pages 359-363

  Baldovino, Simone ^a,b   Moliner, Antoni Montserrat ^e   Taruscio, Domenica ^c   Daina, Erica ^d   Roccatello, Dario ^a,b  

^a S GIOVANNI BOSCO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e EUROPEAN COMMISSION   (Belgium)

Author keywords

European Reference Network (ERN); Local health care network; Rare diseases (RD); Registries; Scientific societies

Indexed keywords

ALPORT SYNDROME; AMYOTROPHIC LATERAL SCLEROSIS; ARNOLD CHIARI MALFORMATION; ARTICLE; CONGENITAL BLOOD VESSEL MALFORMATION; DISEASE REGISTRY; EUROPE; HEALTH CARE POLICY; HISTOLOGY; PUBLIC HEALTH; RARE DISEASE; RENDU OSLER WEBER DISEASE; CLASSIFICATION; CODING; DISEASE MANAGEMENT; HUMAN; INTERNATIONAL COOPERATION; ITALY; ORGANIZATION AND MANAGEMENT; PSYCHOLOGY; QUALITY OF LIFE; RARE DISEASES; REGISTER;

CLINICAL CODING; DISEASE MANAGEMENT; EUROPE; HEALTH POLICY; HUMANS; INTERNATIONAL COOPERATION; ITALY; QUALITY OF LIFE; RARE DISEASES; REGISTRIES;

EID: 84975784705     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Moliner AM. Creating a European Union framework for actions in the field of rare diseases. Adv Exp Med Biol 2010; 686: 457-473
2. Aronson JK. Rare diseases and orphan drugs. Br J Clin Pharmacol 2006; 61 (3): 243-245
3. Aymé S, Bellet B, Rath A. Rare diseases in ICD11: making rare diseases visible in health information systems through appropriate coding. Orphanet J Rare Dis 2015; 10: 35
4. Panteli D, Wagner C, Verheyen F, Busse R. Continuity of care in the cross-border context: insights from a survey of German patients treated abroad. Eur J Public Health 2015; 25 (4): 557-563
5. Azzopardi-Muscat N, Brand H. Will European Reference Networks herald a new era of care for patients with rare and complex diseases? Eur J Public Health 2015; 25 (3): 362-363
6. Joppi R, Bertele V, Garattini S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol 2013; 69 (4): 1009-1024
7. Forrest CB, Bartek RJ, Rubinstein Y, Groft SC. The case for a global rare-diseases registry. Lancet 2011; 377 (9771): 1057-1059
8. Valkova L, Ospanova D, Grjibovski A, et al. Urban-rural variations in survival of patients with soft tissue sarcomas in Northwest Russia in 2000-2011: a registrybased study. Eur J Public Health 2014; 24 (Suppl 2): cku165.089
9. Buscarini E, Leandro G, Conte D, et al. Natural history and outcome of hepatic vascular malformations in a large cohort of patients with hereditary hemorrhagic teleangiectasia. Dig Dis Sci 2011; 56 (7): 2166-2178
10. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5 (10): 1844-1859
11. Gross O, Licht C, Anders HJ, et al. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 2012; 81 (5): 494-501
12. Redig AJ, Jänne PA. Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol 2015; 33 (9): 975-977
13. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015; 373 (8): 726-736
14. Taruscio D, Groft SC, Cederroth H, et al. Undiagnosed Diseases Network International (UDNI): White paper for global actions to meet patient needs. Mol Genet Metab 2015; 116 (4): 223-225
15. Baldovino S, Menegatti E, Modena V, Maspoli M, Avanzi F, Roccatello D. Piedmont and Aosta Valley inter-regional network in the context of the Italian National Network for rare diseases. Blood Transfus 2014; 12 (Suppl 3): s617-s620
16. Taruscio D, Kodra Y, Ferrari G, Vittozzi L. The Italian National Rare Diseases Registry. Blood Transfus 2014; 12 (3): 606-613
17. Salvatore M, Magrelli A, Taruscio D. The role of microRNAs in the biology of rare diseases. Int J Mol Sci 2011; 12 (10): 6733-6742
18. Taruscio D, Carbone P, Granata O, Baldi F, Mantovani A. Folic acid and primary prevention of birth defects. Biofactors 2011; 37 (4): 280-284
19. Censi F, Tosto F, Floridia G, et al. The Italian national external quality assessment program in molecular genetic testing: results of the VII round (2010-2011). Biomed Res Int 2013; 2013
20. Taruscio D, Arriola L, Baldi F, et al. European recommendations for primary prevention of congenital anomalies: a joined effort of EUROCAT and EUROPLAN projects to facilitate inclusion of this topic in the national rare disease plans. Public Health Genomics 2014; 17 (2): 115-123
21. Taruscio D, Gentile AE, De Santis M, et al. EUROPLAN: a project to support the development of national plans on rare diseases in Europe. Public Health Genomics 2013; 16 (6): 278-287
22. Taruscio D, Gainotti S, Mollo E, et al. The current situation and needs of rare disease registries in Europe. Public Health Genomics 2013; 16 (6): 288-298
23. Taruscio D, Morciano C, Laricchiuta P, Mincarone P, Consortium R-B. RAREBestpractices: a platform for sharing best practices for the management of rare diseases. Rare Dis Orphan Drugs 2014; 1 (1).
24. Manson J, Ritchie K, Hilton Boon M. RARE-Best Practices: Addressing inequalities in rare disease management. Eur J Public Health 2014; 24 (Suppl 2): cku166.143
25. Taylor CM, Karet Frankl FE. Developing a strategy for the management of rare diseases. BMJ 2012; 344: e2417
26. Peila E, Fogliano MR, Crosasso P, et al. Extemporaneous orphan drugs and preparations for rare diseases: organisation and management of an inter-regional network. EJHP Pract 2011; 17 (3): 40-46
27. Ciaramitaro P, Baldovino S, Roccatello D, Bottacchi E, Faccani G. Chiari and Syringomyelia Consortium: a model of multidisciplinary and sharing path for rare diseases. Neurol Sci 2011; 32 (S3): 271-273
28. Bazzan M, Vaccarino A, Stella S, et al. Thrombotic recurrences and bleeding events in APS vascular patients: a review from the literature and a comparison with the APS Piedmont Cohort. Autoimmun Rev 2013; 12 (8): 826-831
29. Sciascia S, Roccatello D, Bertero MT, et al. 8-isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study. Inflamm Res 2012; 61 (8): 809-816
30. Rossi D, Russo A, Manna E, et al. The role of nail-videocapillaroscopy in early diagnosis of scleroderma. Autoimmun Rev 2013; 12 (8): 821-825
31. Baldovino S, Montin D, Martino S, Sciascia S, Menegatti E, Roccatello D. Common variable immunodeficiency: crossroads between infections, inflammation and autoimmunity. Autoimmun Rev 2013; 12 (8): 796-801
32. Biagi F, Balduzzi D, Delvino P, Schiepatti A, Klersy C, Corazza GR. Prevalence of Whipple’s disease in north-western Italy. Eur J Clin Microbiol Infect Dis 2015; 34 (7): 1347-1348
33. Migliaretti G, Berchialla P, Dalmasso P, Cavallo F, Chiò A. Amyotrophic lateral sclerosis in Piedmont (Italy): a Bayesian spatial analysis of the incident cases. Amyotroph Lateral Scler Front Degener 2013; 14 (1): 58-65
34. Sciascia S, Bertolaccini ML, Baldovino S, Roccatello D, Khamashta MA, Sanna G. Central nervous system involvement in systemic lupus erythematosus: overview on classification criteria. Autoimmun Rev 2013; 12 (3): 426-429
35. Mereuta OM, Baldovino S, Errichiello E, et al. Systemic AA amyloidosis as a unique manifestation of a combined mutation of TNFRSF1A and MEFV genes. Amyloid 2013; 20 (2): 122-126.